lol, yep they certainly capitalised at an opportune time, now we get to see the opportunity arise from it all.
I wouldn't worry about not knowing about it last year, with the focus groups (specialists who will recommend the Brevagen test) identifying a $150m a year market with women who have test negative to the Myriad Genetics test and the potential 1 million women ($500m market) who have a positive mammogram, we could quite possibly see significant value added just for the US potential alone.
report, page-3
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
